masthead-news

News & Events

2018 American Society of Clinical Oncology (ASCO)

HTG’s 1:1 Promise Cdx Partnerships, Personalized.

HTG will be at the 2018 ASCO Annual Meeting. Stop by and learn how our NGS-based HTG EdgeSeq chemistry and automation can help shape the future of oncology.

McCormick Place | Chicago, IL | June 1 - June 5 | Booth #4113 | Meeting Room MR1 on Exhibit Hall Floor

Read More

Posted on:
 

HTG Molecular Diagnostics Completes Initial Technical Feasibility Testing with QIAGEN GeneReader NGS System

TUCSON, Ariz., March 23, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents, and services for molecular profiling applications, today announced that its HTG EdgeSeq technology has been successfully adapted for use with the QIAGEN GeneReader NGS System based on the results of initial technical feasibility tests. Results from samples tested with the HTG EdgeSeq DLBCL Cell of Origin Assay gene panel adapted for detection with the GeneReader NGS System showed strong correlation (r = 0.98) to data previously generated on the MiSeq sequencer.

Read More

Posted on:
 

HTG Molecular Diagnostics and Firalis Announce Agreement to Develop a Theranostic Tool to Predict Response to Anti-TNF-alpha Therapies for Rheumatoid Arthritis

TUCSON, Ariz. and HUNINGUE, France, July 06, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, and Firalis S.A. (“Firalis”), a provider of bioanalytical services and biomarker-based products to biopharma, to biotechnology companies, and to academia, today announced an agreement to develop a next‑generation sequencing (NGS)-based theranostic tool to identify likely non-responders from responders to anti‑TNFα therapy for rheumatoid arthritis (RA).

Read More

Posted on:
 

HTG Molecular Diagnostics Announces Distribution Agreements with Gamidor in Israel and Durviz in Spain and Portugal

TUCSON, Ariz., April 11, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), (“HTG”), a provider of instruments and reagents for molecular profiling applications, today announced distribution agreements with Gamidor Diagnostics (“Gamidor”) in Israel and Durviz s.l. Parque Tecnológico de Valencia (“Durviz”) in Spain and Portugal to manage distribution of HTG’s next generation sequencing (NGS)-based products.

Read More

Posted on:

Page last updated March 20, 2023